Yinling Hu

Dr. Yinling Hu


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SPSe-Young Park
Se-Young Park
BHByeong-Oh Hwang
Byeong-Oh Hwang
MLMihwa Lim
Mihwa Lim
SOSeung-Ho Ok
Seung-Ho Ok
SLSun-Kyoung Lee
Sun-Kyoung Lee
NSNa-Young Song
Na-Young Song
It is well-known that microbiota dysbiosis is closely associated with numerous diseases in the human body. The oral cavity and gut are the two largest microbial habitats, playing a major role in microbiome-associated diseases. Even though the oral cavity and gut are continuous regions connected through the gastrointestinal tract, the oral and gut microbiome profiles are well-segregated due to the oral–gut barrier. However, the oral microbiota can translocate to the intestinal mucosa in conditions of the oral–gut barrier dysfunction. Inversely, the gut-to-oral microbial transmission occurs as well in inter- and intrapersonal manners. Recently, it has been reported that oral and gut microbiomes interdependently regulate physiological functions and pathological processes. Oral-to-gut and gut-to-oral microbial transmissions can shape and/or reshape the microbial ecosystem in both habitats, eventually modulating pathogenesis of disease. However, the oral–gut microbial interaction in pathogenesis has been underappreciated to date. Here, we will highlight the oral–gut microbiome crosstalk and its implications in the pathogenesis of the gastrointestinal disease and cancer. Better understanding the role of the oral–gut microbiome axis in pathogenesis will be advantageous for precise diagnosis/prognosis and effective treatment.

1 April 2013 in Cancer Cell
Verified
Journal Article
Closed access
ZXZuoxiang Xiao
Zuoxiang Xiao
QJQun Jiang
Qun Jiang
JWJami Willette-Brown
Jami Willette-Brown
SXSichuan Xi
Sichuan Xi
FZFeng Zhu
Feng Zhu
YHYinling Hu
Yinling Hu

30 September 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
BMBradley N. Martin
Bradley N. Martin
CWChenhui Wang
Chenhui Wang
JWJami Willette-Brown
Jami Willette-Brown
THTomasz Herjan
Tomasz Herjan
MGMuhammet F. Gulen
Muhammet F. Gulen
XLXiaoxia Li
Xiaoxia Li
The inflammasomes are multiprotein complexes that activate caspase-1 in response to infections and stress, resulting in the secretion of pro-inflammatory cytokines. Here we report that IκB kinase α (IKKα) is a critical negative regulator of apoptosis-associated specklike protein containing a C-terminal caspase-activation-andrecruitment (CARD) domain (ASC)-dependent inflammasomes. IKKα controls the inflammasome at the level of the adaptor ASC, which interacts with IKKα in the nucleus of resting macrophages in an IKKα kinase-dependent manner. Loss of IKKα kinase activity results in inflammasome hyperactivation. Mechanistically, the downstream nuclear effector IKK-related kinase (IKKi) facilitates translocation of ASC from the nucleus to the perinuclear area during inflammasome activation. ASC remains under the control of IKKα in the perinuclear area following translocation of the ASC/IKKα complex. Signal 2 of NLRP3 activation leads to inhibition of IKKα kinase activity through the recruitment of PP2A, allowing ASC to participate in NLRP3 inflammasome assembly. Taken together, these findings reveal a IKKi-IKKα-ASC axis that serves as a common regulatory mechanism for ASC-dependent inflammasomes.

1 April 2017 in Cell Host & Microbe
Verified
Journal Article
Closed access
FZFeng Zhu
Feng Zhu
JWJami Willette-Brown
Jami Willette-Brown
NSNa-Young Song
Na-Young Song
DLDakshayani Lomada
Dakshayani Lomada
YSYongmei Song
Yongmei Song
YHYinling Hu
Yinling Hu

8 January 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
NSNa-Young Song
Na-Young Song
FZFeng Zhu
Feng Zhu
ZWZining Wang
Zining Wang
JWJami Willette-Brown
Jami Willette-Brown
SXSichuan Xi
Sichuan Xi
YHYinling Hu
Yinling Hu
Significance: Reactive oxygen species (ROS) can promote tumorigenesis or kill cancer cells. How different cancer-associated genetic alterations regulate ROS balance and outcome is of great importance for the design of rational cancer treatments, many of which affect ROS metabolism and sensing. Kras activation induces a ROS defense system and cell senescence, which counteract its oncogenic activity. KRAS -activating mutations are accompanied by IKKα loss mutations that result in elevated NOX2 but decreased expression of the NRF2 ROS defense system. Thus, IKKα ablation turns the antitumorigenic effect of Kras-induced ROS to a protumorigenic effect that enhances Kras-induced progression of lung adenocarcinoma (ADC). Restoration of IKKα activity or inhibition of the pathways activated on its loss may offer new opportunities for ADC treatment.

26 March 2018 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
XWXin Wang
Xin Wang
ZGZane Gray
Zane Gray
JWJami Willette-Brown
Jami Willette-Brown
FZFeng Zhu
Feng Zhu
GSGongping Shi
Gongping Shi
YHYinling Hu
Yinling Hu
Human lung squamous cell carcinoma (SCC) is highly associated with increased pulmonary macrophage infiltration. Previously, we showed that marked pulmonary infiltrating macrophages were required for spontaneous lung SCC development in a mouse model (L-Ikkα KA/KA , KA/KA) that resembles human lung SCC. Interestingly the lung SCC-associated macrophages specifically express elevated inducible nitric oxide synthase (NOS2). However, the role of macrophage NOS2 in lung carcinogenesis has not been explored. Here, we show that NOS2 ablation inhibits macrophage infiltration, fibrosis, and SCC development in the lungs of KA/KA mice. Macrophage NOS2 was found to circulate inflammation and enhance macrophage migration and survival. NOS2 promotes foamy macrophage formation characterized with impaired lipid metabolism. NOS2 null bone marrow transplantation reduces foamy macrophage numbers and carcinogenesis in KA/KA chimaeras. This finding sheds light on a new mechanism by which macrophage NOS2 increases pulmonary inflammatory responses and macrophage survival and impairs macrophage lipid metabolism, thereby promoting lung SCC formation.